GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
After market 23:00:00 | |||
| 67.72 USD | -0.21% |
|
67.5 | -0.32% |
| 05-14 | Transcript : Gilead Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM | |
| 05-09 | Declaration of Voting Results by Gilead Sciences | CI |
| Sales 2024 * | 27.6B 2,173B | Sales 2025 * | 27.98B 2,203B | Capitalization | 84.36B 6,643B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M 31.73B | Net income 2025 * | 6.35B 500B | EV / Sales 2024 * | 3.71 x |
| Net Debt 2024 * | 18.15B 1,429B | Net Debt 2025 * | 12.68B 999B | EV / Sales 2025 * | 3.47 x |
| P/E ratio 2024 * |
194
x | P/E ratio 2025 * |
13.1
x | Employees | 18,000 |
| Yield 2024 * |
4.57% | Yield 2025 * |
4.79% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | -0.32% | ||
| 1 week | +2.67% | ||
| Current month | +3.87% | ||
| 1 month | +1.18% | ||
| 3 months | -5.39% | ||
| 6 months | -10.25% | ||
| Current year | -16.41% |
1 week
66.13
68.37
1 month
64.3368.37
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 28/02/19 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 31/12/15 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 11/04/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 16/10/20 |
| Director/Board Member | 71 | 31/12/17 | |
Ted Love
BRD | Director/Board Member | 65 | 01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +10.97% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 67.72 | -0.21% | 3,579,078 |
| 16/05/24 | 67.86 | +1.27% | 4,831,970 |
| 15/05/24 | 67.01 | -0.95% | 7,532,064 |
| 14/05/24 | 67.65 | +0.16% | 4,356,239 |
| 13/05/24 | 67.54 | +2.40% | 6,736,457 |
Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.41% | 84.54B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- GILD Stock
